Sign in

    Jake Soucheray

    Research Analyst at Craig-Hallum Capital Group LLC

    Jake Soucheray is an Associate Analyst at Craig-Hallum Capital Group LLC, specializing in equity research for the healthcare sector. He covers public companies such as Delcath Systems and participates in earnings calls and investor communications, contributing research insights on company performance and industry trends. Soucheray began his analyst career at Craig-Hallum and has held this position since at least early 2024. He is professionally credentialed as a registered broker with FINRA (CRD#: 7989780), demonstrating compliance with securities industry regulations and licensing requirements.

    Jake Soucheray's questions to DELCATH SYSTEMS (DCTH) leadership

    Jake Soucheray's questions to DELCATH SYSTEMS (DCTH) leadership • Q2 2025

    Question

    Jake Soucheray, on behalf of Chase Knickerbocker at Craig-Hallum, asked if joining the NDRA program has created more urgency for centers to become active. He also requested guidance on the expected ramp-up in R&D spending for new clinical trials.

    Answer

    CEO Gerard Michel stated the NDRA program has not created a noticeable increase in urgency, as site activation is complex with many gating items, but it does ease financial conversations. CFO Sandra Pennell projected R&D expenses would increase by another 40% in Q3 and 25-30% in Q4 over Q3, for a full-year increase of about 140% over 2024.

    Ask Fintool Equity Research AI